The Evidence on Ozempic to Treat Addiction
Listen to the original audio · Transcribed with NVIDIA Parakeet · Timestamps stay in sync with the live audio
This is the New Yorker Radio Hour, a co-production of WNYC Studios and The New Yorker. This is the New Yorker Radio Hour. I'm David Remnick. It's rare that a drug has had as big an impact on our lives as Ozempic.
It's been on the market for a relatively short time, and something like 12% of Americans have taken Ozempic or one of the others in its class, the GLP1 drugs. Now 12% is a lot, but when you consider that around 40% of us are obese, we're probably not at the plateau for GLP1 drugs. And because these are relatively new drugs, there's a lot that scientists don't know about them yet. Drew Coular is a contributing writer covering medicine and healthcare, and he just published a piece of reporting in the New Yorker called Kenosempic Cure Addiction. This segment will be called Everyone's Doin'it, doing it, doing it.
God. Are you willing to admit it's a wonder drug? Uh I don't know about a wonder drug. But it's the closest thing we have. So how did you get clued into this research on GLP1 drugs, Ozampic, Wigovi, and and and so many others?
We already have this episode, so unlocking it is cheap and permanent: the full transcript (20 minutes, 3,604 words), segment and word-level timestamps, and .txt, .srt, .vtt and word-level JSON downloads, as many times as you like, forever.
No account needed, we create one from your checkout email. With credits it is 1 credit; packs start at 10 episodes for $5, and monthly plans are cheaper still.